{
  "company": "Illumina",
  "ticker": "ILMN",
  "period": {
    "from": "2026-02-26",
    "to": "2026-03-28",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 21,
    "negative": 28,
    "neutral": 43
  },
  "synthesis": {
    "executive_summary": "**Executive Summary: Illumina (ILMN) Sentiment Analysis (2026-02-26 to 2026-03-28)**\n\nSentiment analysis for Illumina (ILMN) during the period of February 26 to March 28, 2026, indicates a predominantly neutral to slightly negative market perception. Out of 92 tracked items, 43 (46.7%) were classified as neutral, 28 (30.4%) as negative, and 21 (22.8%) as positive. Key drivers for positive sentiment included instances of ILMN stock outperforming competitors and reports of stronger-than-expected Q3 earnings and FY2026 guidance. Conversely, negative sentiment was primarily driven by bearish stock price forecasts and observed declines in share value. The prevalence of neutral commentary suggests a cautious or wait-and-see approach from a significant portion of market observers.\n\nSignificant positive events included Illumina's stock rising by 2.96% on a strong trading day, outperforming broader market indices, and the expansion of its precision oncology testing partnership with Labcorp to advance next-generation sequencing (NGS). On the negative side, a notable event was the forecast of Illumina's price giving in to negative pressure, with analysts predicting further decline and targeting a key support level. While several highly negative sentiment items were identified, many originated from scientific research publications, which may not directly reflect the company's immediate financial performance or market sentiment.",
    "key_findings": [
      "✓ Illumina Inc. stock outperforms competitors on strong trading day",
      "✓ Is Illumina (ILMN) a Great Long-Term Investment?",
      "✓ Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN",
      "✗ Recalibrating the epigenetic clock reveals divergent DNA methylation age signatures across schizophrenia, bipolar disorder and major depressive disorder.",
      "✗ hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types.",
      "✗ Illumina price gives in to negative pressure - Forecast today - 24-03-2026"
    ],
    "overall_sentiment": "mixed"
  },
  "top_positive": [
    {
      "title": "Illumina Inc. stock outperforms competitors on strong trading day",
      "date": "2026-03-19",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "Is Illumina (ILMN) a Great Long-Term Investment?",
      "date": "2026-03-22",
      "source": "reddit",
      "score": 0.625
    },
    {
      "title": "Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN",
      "date": "2026-03-15",
      "source": "alpha_vantage",
      "score": 0.612
    },
    {
      "title": "What are you doing? You really think I'm going to give up that easily? VENOMSHAK! FIREBRAND! DARKHEART! ICE DAGGER! WINDFORSE! GHOSTWALKER! ILLUMINA!",
      "date": "2026-02-26",
      "source": "reddit",
      "score": 0.603
    },
    {
      "title": "Illumina and Labcorp Expand Precision Oncology Testing Partnership",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.518
    },
    {
      "title": "US Multiomic Market Set to Boom Rapidly, Witnessing Strong",
      "date": "2026-03-24",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "Culture and Metagenomic Insights into the Ear Microbiota in Dogs with Healthy Ears and Otitis Externa.",
      "date": "2026 Mar 6",
      "source": "pubmed",
      "score": 0.402
    },
    {
      "title": "Help finding an analysis pipeline for Illumina scRNAseq with SNT cell hashing",
      "date": "2026-03-03",
      "source": "reddit",
      "score": 0.402
    },
    {
      "title": "Molecular Transducers of Physical Activity Consortium (MoTrPAC): Initial Insights into the Dynamic Human Responses to Exercise.",
      "date": "2026 Mar 5",
      "source": "pubmed",
      "score": 0.382
    },
    {
      "title": "Books like the illuminae files",
      "date": "2026-03-23",
      "source": "reddit",
      "score": 0.361
    }
  ],
  "top_negative": [
    {
      "title": "Recalibrating the epigenetic clock reveals divergent DNA methylation age signatures across schizophrenia, bipolar disorder and major depressive disorder.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.821
    },
    {
      "title": "hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types.",
      "date": "2026-03-28",
      "source": "pubmed",
      "score": -0.791
    },
    {
      "title": "Illumina price gives in to negative pressure - Forecast today - 24-03-2026",
      "date": "2026-03-24",
      "source": "alpha_vantage",
      "score": -0.71
    },
    {
      "title": "Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.66
    },
    {
      "title": "PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.",
      "date": "2026-03-28",
      "source": "pubmed",
      "score": -0.66
    },
    {
      "title": "Illumina Says China Removed Ban on Importing DNA Sequencers",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": -0.557
    },
    {
      "title": "No association between genetic ancestry and exome sequencing-based diagnosis of inborn errors of metabolism.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.557
    },
    {
      "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.",
      "date": "2026 Mar 1",
      "source": "pubmed",
      "score": -0.46
    },
    {
      "title": "Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
      "date": "2026-03-17",
      "source": "alpha_vantage",
      "score": -0.458
    },
    {
      "title": "Circulating Factors Induce Cardiomyopathy after Burn Injury.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": -0.421
    }
  ],
  "raw_data": {
    "total_items": 92,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "Assessing Illumina (ILMN) Valuation After New Labcorp And Preventive Genomics Alliances",
        "url": "https://www.sahmcapital.com/news/content/assessing-illumina-ilmn-valuation-after-new-labcorp-and-preventive-genomics-alliances-2026-03-24",
        "date": "2026-03-25",
        "summary": "Illumina has recently expanded its collaborations with Labcorp and entered a new consortium, driving its stock momentum, with a 5.2% 30-day return. Despite recent gains, the 1-year return is strong, contrasting with weaker 3 and 5-year returns, indicating a recent upturn. The company is currently valued at a discount to analyst targets and an intrinsic value estimate of $136.05, raising questions about whether current pricing fully accounts for future growth from these new alliances.",
        "sentiment_score": 0.29055,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/illumina-inc-stock-faces-headwinds-amid-grail-divestiture-scrutiny-and/68977501",
        "date": "2026-03-24",
        "summary": "Illumina Inc. is facing significant challenges, including regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector. Despite a robust balance sheet and ongoing R&D investments, the company's stock is under pressure from softening demand in genomic sequencing, increased competition, and lingering legal ramifications from the Grail divestiture. Investors are closely watching if Illumina can successfully navigate these headwinds and recover its growth trajectory.",
        "sentiment_score": -0.491801,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina price gives in to negative pressure - Forecast today - 24-03-2026",
        "url": "https://www.economies.com/stocks/united-states-analysis/illumina-price-gives-in-to-negative-pressure---forecast-today---24-03-2026-125749",
        "date": "2026-03-24",
        "summary": "Illumina's (ILMN) stock price experienced a decline due to a short-term corrective bearish wave and negative pressure from its 50-day SMA, coupled with overbought Stochastic indicators. Analysts predict further decline, targeting a key support level at $115.30 unless it breaks above $128.15. The article also provides bearish forecasts for Alibaba and Snap, and a bullish forecast for Western Digital.",
        "sentiment_score": 0.031374,
        "sentiment_label": "Neutral",
        "relevance_score": 0.343849,
        "sentiment": {
          "label": "negative",
          "score": -0.71,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "US Multiomic Market Set to Boom Rapidly, Witnessing Strong",
        "url": "https://www.openpr.com/news/4437722/us-multiomic-market-set-to-boom-rapidly-witnessing-strong",
        "date": "2026-03-24",
        "summary": "Coherent Market Insights has released a new research study on the Global \"US Multiomic Market\" forecasting strong growth through 2033. The report segments the market by type (Genomics, Proteomics, Metabolomics) and applications (Precision Medicine, Drug Discovery, Clinical Research), and provides competitive and regional analysis. Key players include Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc.",
        "sentiment_score": 0.430879,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "TruPath™ Genome enables deeper insight into complex genomic regions",
        "url": "https://www.illumina.com/company/video-hub/U4l4GnIUsLw.html",
        "date": "2026-03-23",
        "summary": "This article introduces Illumina's TruPath™ Genome, a new tool designed to offer deeper insights into complex genomic regions. Steve Barnard explains how this approach addresses research challenges and enables comprehensive genome interpretation without needing changes to existing sequencing infrastructure. The technology aims to advance genomic research by providing more detailed data.",
        "sentiment_score": 0.48899,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Nordea Investment Management AB Has $124.15 Million Stake in Illumina, Inc. $ILMN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-nordea-investment-management-ab-has-12415-million-stake-in-illumina-inc-ilmn-2026-03-23/",
        "date": "2026-03-23",
        "summary": "Nordea Investment Management AB significantly increased its stake in Illumina, Inc. by 2,792.2% in Q4, acquiring 911,843 additional shares to hold a total of 944,500 shares valued at approximately $124.15 million. This move comes as Illumina reported Q4 earnings that beat estimates, with EPS of $1.35 and revenue of $1.16 billion, and issued promising FY2026 guidance. Analyst sentiment for Illumina is mixed, with an average \"Hold\" rating and an average price target of $129.69, despite some firms ",
        "sentiment_score": 0.028138,
        "sentiment_label": "Neutral",
        "relevance_score": 0.323951,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Here’s Why Illumina Could Continue Its 47% Last Year Rally",
        "url": "https://www.tikr.com/blog/heres-why-illumina-could-continue-its-47-last-year-rally",
        "date": "2026-03-22",
        "summary": "Illumina's stock rally is supported by strong Q4 2025 earnings, particularly 20% clinical consumables growth outside China, and strategic partnerships. The company projects significant revenue and EPS growth for 2026, driven by its NovaSeq X platform and recent SomaLogic acquisition. While analysts have a mixed view, TIKR's valuation model suggests a higher price target, emphasizing the operational re-rating and margin expansion potential.",
        "sentiment_score": 0.429449,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina and Labcorp Expand Precision Oncology Testing Partnership",
        "url": "https://oncodaily.com/techology/illumina471908",
        "date": "2026-03-20",
        "summary": "Illumina and Labcorp have expanded their collaboration to advance precision oncology through next-generation sequencing (NGS) by developing distributed IVD test offerings and co-commercializing liquid and tissue biopsy assays. This partnership aims to improve access to advanced biomarker testing in community health systems and underserved regions by enabling local testing and supporting targeted therapy development. The initiative builds on strong scientific collaboration and clinical evidence, ",
        "sentiment_score": 0.416738,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.518,
          "confidence": 0.52
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina Says China Removed Ban on Importing DNA Sequencers",
        "url": "http://www.msn.com/en-us/money/markets/illumina-says-china-removed-ban-on-importing-dna-sequencers/ar-AA1PSQbj?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-20",
        "summary": "Illumina announced that China has removed its ban on importing DNA sequencers, a development that could significantly impact the company's business within the Chinese market. This decision follows complex regulatory and trade discussions, potentially opening new avenues for medical and research advancements in China.",
        "sentiment_score": 0.417679,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-93ccfb0e-eb36751a88f5?gaa_at=eafs&gaa_n=AWEtsqe7eHprthSRx3upDmS6aWnTYfkvES6M41erV5CFCoI2NOh7Ch5omi0l&gaa_ts=69bd9ed7&gaa_sig=E8NH-VjelRzGPxYbHqnfi5Q7xeXbjKIs5uYjvloMe12rxmctniM1Ty3cFWr_4nTNGzuwohdGYZelzV95j9vqog%3D%3D",
        "date": "2026-03-19",
        "summary": "Illumina Inc. (ILMN) saw its stock rise by 2.96% to $126.59 on Thursday, marking its fifth consecutive day of gains. This performance occurred on a generally poor trading day where the S&P 500 Index and Dow Jones Industrial Average both experienced declines. The article highlights Illumina's strong showing despite a broader market downturn.",
        "sentiment_score": 0.541023,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
        "url": "https://www.marketwatch.com/data-news/illumina-inc-stock-underperforms-tuesday-when-compared-to-competitors-despite-daily-gains-7474d609-04bf7c4c380b?gaa_at=eafs&gaa_n=AWEtsqeEHGRJbJEVRMUgx3rUo5ze8PYBrB9A_RM3rVPCBRZP9AeQ-8Ncj-gn&gaa_ts=69ba44f6&gaa_sig=I8bkSEMPiuoVauoMrBp13HoZfBQ3XsyyYOp3r7ORGIBNmBPtOQAJG5BCSEMzw4u7cySN59I196U71fm0TNBBWw%3D%3D",
        "date": "2026-03-17",
        "summary": "Illumina Inc.'s stock (ILMN) advanced 1.31% on Tuesday, closing at $120.84, marking its third consecutive day of gains. Despite this positive movement, the stock underperformed compared to the broader market, as the S&P 500 Index rose 0.25% and the Dow Jones Industrial Average increased by 0.10%.",
        "sentiment_score": 0.115016,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.458,
          "confidence": 0.46
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-bamco-inc-ny-sells-39378-shares-of-illumina-inc-ilmn-2026-03-16/",
        "date": "2026-03-16",
        "summary": "Bamco Inc. NY sold 39,378 shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, reducing its stake by 15.9% to 208,094 shares valued at approximately $19.76 million. The company recently reported Q3 earnings per share of $1.35 and revenue of $1.16 billion, beating analyst expectations. Despite a consensus \"Hold\" rating from analysts with an average target price of $129.69, SVP Patricia Leckman also sold 2,370 shares, further decreasing insider holdings.",
        "sentiment_score": 0.113612,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina, Inc. $ILMN Stake Lessened by Cannell & Spears LLC",
        "url": "https://www.marketbeat.com/instant-alerts/filing-illumina-inc-ilmn-stake-lessened-by-cannell-spears-llc-2026-03-15/",
        "date": "2026-03-15",
        "summary": "Cannell & Spears LLC reduced its stake in Illumina (NASDAQ:ILMN) by 3.7% in Q3, selling 9,119 shares but still holding 239,301 shares valued at approximately $22.73 million. This comes as institutional investors now own 89.42% of the company's stock. Additionally, SVP Patricia Leckman sold 2,370 shares, decreasing her position by 12.68%, while Illumina reported strong Q4 results, exceeding revenue and EPS expectations.",
        "sentiment_score": 0.091639,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-quinn-opportunity-partners-llc-sells-62423-shares-of-illumina-inc-ilmn-2026-03-14/",
        "date": "2026-03-15",
        "summary": "Quinn Opportunity Partners LLC significantly reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by selling 62,423 shares in Q3, now holding 35,264 shares valued at $3.35 million. This follows other institutional investors modifying their positions and an insider sale by SVP Patricia Leckman. Despite the sales, Illumina reported stronger-than-expected Q3 earnings and revenue, providing FY2026 guidance, and analysts currently give the stock a \"Hold\" rating with a target price of $129.69.",
        "sentiment_score": 0.073455,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Illumina Inc. stock outperforms competitors despite losses on the day",
        "url": "https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-despite-losses-on-the-day-ea1043aa-ddd7ffa5f125?gaa_at=eafs&gaa_n=AWEtsqeRPUKBFJlPUtpzoqxqNaiV_ohW0kCf3qPlEFTXux66zv4gcLQjw67n&gaa_ts=69b781e0&gaa_sig=x7XnTAwbCFN5LUHbwnPSQ19ALSY65e7L-xXyL9xk5vXGQjdo12S0-KY67k8Jazlp2-f_GKsu2MsB_w1RIWu-Ng%3D%3D",
        "date": "2026-03-10",
        "summary": "Illumina Inc. (ILMN) shares fell 1.55% to $122.35 on Tuesday, marking its seventh consecutive day of losses, despite an overall grim trading session for the broader stock market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This report highlights Illumina's performance relative to the general market trend.",
        "sentiment_score": -0.205384,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.309,
          "confidence": 0.31
        }
      },
      {
        "source": "alpha_vantage",
        "title": "ARK Investment Management LLC Has $139.41 Million Position in Illumina, Inc. $ILMN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-ark-investment-management-llc-has-13941-million-position-in-illumina-inc-ilmn-2026-03-05/",
        "date": "2026-03-05",
        "summary": "ARK Investment Management LLC increased its stake in Illumina, Inc. by 25.7% in Q3, owning 1,467,879 shares valued at approximately $139.41 million. Illumina recently surpassed quarterly estimates with EPS of $1.35 and revenue of $1.16 billion and provided FY2026 guidance. Analyst ratings are mixed, with a consensus \"Hold\" and an average price target of $129.69.",
        "sentiment_score": 0.253119,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Handelsbanken Fonder AB Boosts Stake in Illumina, Inc. $ILMN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-handelsbanken-fonder-ab-boosts-stake-in-illumina-inc-ilmn-2026-03-03/",
        "date": "2026-03-04",
        "summary": "Handelsbanken Fonder AB increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 27.7% in the third quarter, acquiring an additional 11,200 shares to bring its total holdings to 51,600 shares valued at $4.9 million. This increase follows Illumina's strong Q3 results, where it surpassed EPS and revenue estimates, and provided robust FY2026 guidance. Despite a consensus \"Hold\" rating from analysts with an average price target of $129.69, several institutional investors have recently adjusted their p",
        "sentiment_score": 0.471612,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "pubmed",
        "pmid": "41895717",
        "title": "CD8 PET imaging with [(89)Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.",
        "authors": "Postow MA et al.",
        "journal": "Journal for immunotherapy of cancer",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41895717/",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "pubmed",
        "pmid": "41895699",
        "title": "A genetic association study of iron absorption in adults of East Asian or Northern European ancestry from the Iron Genes in East Asian and Northern European Adults Study (FeGenes).",
        "authors": "Barad A et al.",
        "journal": "The American journal of clinical nutrition",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41895699/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41893782",
        "title": "Hybrid Whole-Genome Sequencing for Genetic Stability Assessment of Infectious Laryngotracheitis Virus Vaccine Strains.",
        "authors": "Jeong HY et al.",
        "journal": "Vaccines",
        "date": "2026 Mar 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41893782/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41893692",
        "title": "Shotgun Metagenomics Reveals Microbial Diversity, Resistome, and Plasmidome in Dairy Cattle Feces.",
        "authors": "Shehla S et al.",
        "journal": "Veterinary sciences",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41893692/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41893667",
        "title": "Culture and Metagenomic Insights into the Ear Microbiota in Dogs with Healthy Ears and Otitis Externa.",
        "authors": "Karakaya E et al.",
        "journal": "Veterinary sciences",
        "date": "2026 Mar 6",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41893667/",
        "sentiment": {
          "label": "positive",
          "score": 0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "pubmed",
        "pmid": "41891186",
        "title": "Nanopore sequencing enables highly accurate genotyping and identification of resistance determinants in key nosocomial pathogens.",
        "authors": "Cottingham H et al.",
        "journal": "Microbial genomics",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41891186/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41891011",
        "title": "Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24.",
        "authors": "Katairo T et al.",
        "journal": "medRxiv : the preprint server for health sciences",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41891011/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41888158",
        "title": "No association between genetic ancestry and exome sequencing-based diagnosis of inborn errors of metabolism.",
        "authors": "Najera J et al.",
        "journal": "NPJ genomic medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41888158/",
        "sentiment": {
          "label": "negative",
          "score": -0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "pubmed",
        "pmid": "41887507",
        "title": "Microbiota Changes in Rumen and Milk Corresponding to Dietary Protein Intake in Transition Dairy Cows.",
        "authors": "Scott J et al.",
        "journal": "Journal of dairy science",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41887507/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41887224",
        "title": "BLOC1S1 variants cause lysosomal and autophagic defects resulting in a hypomyelinating leukodystrophy with epileptic encephalopathy.",
        "authors": "De Pace R et al.",
        "journal": "American journal of human genetics",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41887224/",
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "pubmed",
        "pmid": "41887089",
        "title": "New draft genomes assemblies of Blastocystis isolates from subtypes 1 and 8 confirm conserved synteny, transposable element diversity, and provide insights into pathogenic potential.",
        "authors": "Wawrzyniak I et al.",
        "journal": "Protist",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41887089/",
        "sentiment": {
          "label": "negative",
          "score": -0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "pubmed",
        "pmid": "41886927",
        "title": "Maternal paraben exposure during early pregnancy is associated with altered cord blood DNA methylation: The PREDO cohort.",
        "authors": "Mäkinen M et al.",
        "journal": "Environment international",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41886927/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41885344",
        "title": "The Genome of the Rice Variety Mowanggu Provides Insight Into Resistance to Magnaporthe oryzae.",
        "authors": "Peng W et al.",
        "journal": "Molecular plant pathology",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41885344/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41885266",
        "title": "Circulating Factors Induce Cardiomyopathy after Burn Injury.",
        "authors": "Fortich S et al.",
        "journal": "Journal of the American College of Surgeons",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41885266/",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "pubmed",
        "pmid": "41884442",
        "title": "Genome and transcriptome analyses reveal molecular mechanisms underlying the interaction between Plasmopara viticola and grapevine.",
        "authors": "Karan R et al.",
        "journal": "Frontiers in plant science",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41884442/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41883872",
        "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.",
        "authors": "Qadri F et al.",
        "journal": "Therapeutic advances in medical oncology",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41883715",
        "title": "hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types.",
        "authors": "García Fonseca ÁY et al.",
        "journal": "Cancer informatics",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41883715/",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "41883158",
        "title": "CpGene: A Web Application for Epigenetic Signature Identification from DNA Methylation Arrays.",
        "authors": "Lazaros K et al.",
        "journal": "Bioinformatics (Oxford, England)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41883158/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41881444",
        "title": "Antimicrobial resistance genes and antibiotic use in chronic lung disease: a bronchoscopy study of the lower airways microbiome.",
        "authors": "Kringeland GD et al.",
        "journal": "BMJ open respiratory research",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41881444/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41880578",
        "title": "Immune cell profiling reveals expanded stem cell-like memory T cells in anti-GAD65-associated neurological syndromes.",
        "authors": "Barman S et al.",
        "journal": "Proceedings of the National Academy of Sciences of the United States of America",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41880578/",
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41877305",
        "title": "Recalibrating the epigenetic clock reveals divergent DNA methylation age signatures across schizophrenia, bipolar disorder and major depressive disorder.",
        "authors": "Wu X et al.",
        "journal": "The British journal of psychiatry : the journal of mental science",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41877305/",
        "sentiment": {
          "label": "negative",
          "score": -0.821,
          "confidence": 0.82
        }
      },
      {
        "source": "pubmed",
        "pmid": "41876503",
        "title": "First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.",
        "authors": "Damato A et al.",
        "journal": "Nature communications",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41876503/",
        "sentiment": {
          "label": "negative",
          "score": -0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "pubmed",
        "pmid": "41876443",
        "title": "Genomic landscape reveals the dominance of self-catalytic, high-copy group II introns in PMU-deficient complete genomes of PWB phytoplasmas.",
        "authors": "Kirdat K et al.",
        "journal": "Journal of microbiology (Seoul, Korea)",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41876443/",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "pubmed",
        "pmid": "41876380",
        "title": "Genome sequence data reveal complex and variable ploidy in the amoebozoan Acanthamoeba castellanii.",
        "authors": "Colp MJ et al.",
        "journal": "Genome biology and evolution",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41876380/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41875897",
        "title": "The Electronic Medical Records and Genomics study: Design and analytic framework for assessing the impact of genome-informed risk assessments.",
        "authors": "Limdi N et al.",
        "journal": "American journal of human genetics",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41875897/",
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "pubmed",
        "pmid": "41875895",
        "title": "Return of genome-informed risk-assessment results for common conditions to 23,840 adults and children: An eMERGE network study.",
        "authors": "Lawson LP et al.",
        "journal": "American journal of human genetics",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41875895/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41874879",
        "title": "Molecular surveillance of Bordetella pertussis during the 2024 outbreak in Southeast Brazil: allelic profiles and comparison to vaccine strain.",
        "authors": "Sousa TJ et al.",
        "journal": "Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41874879/",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "pubmed",
        "pmid": "41874698",
        "title": "Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.",
        "authors": "Yoshichika R et al.",
        "journal": "Cancer immunology, immunotherapy : CII",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41874698/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41874183",
        "title": "Genome of Bacillus cereus strain riobravensis, a novel strain isolated from white sorghum dough made for human consumption.",
        "authors": "Hernández-González LI et al.",
        "journal": "Microbiology resource announcements",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41874183/",
        "sentiment": {
          "label": "negative",
          "score": -0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "pubmed",
        "pmid": "41873440",
        "title": "Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study.",
        "authors": "Inciarte A et al.",
        "journal": "The Journal of antimicrobial chemotherapy",
        "date": "2026 Mar 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41873440/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41873129",
        "title": "Changes in the oral microbiota after switching from smoking to exclusive e-cigarette use in an 8-week product-switching trial.",
        "authors": "Alcheva A et al.",
        "journal": "Cancer prevention research (Philadelphia, Pa.)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41873129/",
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "pubmed",
        "pmid": "41872259",
        "title": "A chromosomal-level genome assembly of Phoxinus grumi (Cypriniformes: Leuciscidae).",
        "authors": "Wang J et al.",
        "journal": "Scientific data",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41872259/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41870794",
        "title": "Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification.",
        "authors": "Delbridge C et al.",
        "journal": "Journal of neuro-oncology",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41870794/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41870202",
        "title": "Amplicon sequencing of anaerobic digester microbial communities following Caldicellulosiruptor bescii pretreatment of wastewater substrates.",
        "authors": "Nipko MA et al.",
        "journal": "Microbiology resource announcements",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41870202/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41868108",
        "title": "Starch Overload and Cecal Alkalinization: Impacts on the Intestinal Microbiota and Health of Horses.",
        "authors": "Bustamante CC et al.",
        "journal": "Veterinary and animal science",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41868108/",
        "sentiment": {
          "label": "negative",
          "score": -0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "pubmed",
        "pmid": "41867861",
        "title": "A comprehensive assessment of tandem repeat genotyping methods for Nanopore long-read genomes.",
        "authors": "Aliyev E et al.",
        "journal": "bioRxiv : the preprint server for biology",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41867861/",
        "sentiment": {
          "label": "positive",
          "score": 0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "pubmed",
        "pmid": "41867848",
        "title": "Molecular Transducers of Physical Activity Consortium (MoTrPAC): Initial Insights into the Dynamic Human Responses to Exercise.",
        "authors": "MoTrPAC Study Group et al.",
        "journal": "bioRxiv : the preprint server for biology",
        "date": "2026 Mar 5",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41867848/",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41867745",
        "title": "Divalent siRNA for prion disease.",
        "authors": "Gentile JE et al.",
        "journal": "bioRxiv : the preprint server for biology",
        "date": "2026 Mar 5",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41867745/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41867179",
        "title": "Temporal trends in Plasmodium vivax diversity in eastern Cambodia evidence declining transmission.",
        "authors": "Eam R et al.",
        "journal": "medRxiv : the preprint server for health sciences",
        "date": "2026 Mar 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41867179/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41864215",
        "title": "Lineage dynamics of invasive Escherichia coli isolates in the Netherlands from 1975 to 2021: a retrospective longitudinal genomic analysis.",
        "authors": "Snaith AE et al.",
        "journal": "The Lancet. Microbe",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41864215/",
        "sentiment": {
          "label": "negative",
          "score": -0.052,
          "confidence": 0.05
        }
      },
      {
        "source": "pubmed",
        "pmid": "41862707",
        "title": "Real-world clinical utility of tumor whole-genome sequencing in solid cancers.",
        "authors": "van Putten J et al.",
        "journal": "Nature medicine",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41862707/",
        "sentiment": {
          "label": "negative",
          "score": -0.25,
          "confidence": 0.25
        }
      },
      {
        "source": "pubmed",
        "pmid": "41862495",
        "title": "Chromosome-scale Genome Assembly of the Critically Endangered Blue-crowned Laughingthrush (Pterorhinus courtoisi, Leiothrichidae).",
        "authors": "Ouyang Y et al.",
        "journal": "Scientific data",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41862495/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41862477",
        "title": "Profiling of 5-hydroxymethylcytosine in blood reveals preferential enrichment at exon-intron junctions and predictive value for Parkinson's disease.",
        "authors": "Antczak P et al.",
        "journal": "NPJ Parkinson's disease",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41862477/",
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861829",
        "title": "Integrated drivers of basal and acute immunity in diverse human populations.",
        "authors": "Hegab Souquette A et al.",
        "journal": "Cell reports. Medicine",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861829/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861668",
        "title": "Decoding genotypic antimicrobial resistance amongst colistin-resistant Gram-negative bloodstream isolates at a South African academic healthcare facility.",
        "authors": "Jaglal P et al.",
        "journal": "Diagnostic microbiology and infectious disease",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861668/",
        "sentiment": {
          "label": "negative",
          "score": -0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861625",
        "title": "Integrated redescription of Leidyana gryllorum in Acheta domesticus: Uncovering gregarine diversity in Grylloidea.",
        "authors": "Bessette E et al.",
        "journal": "European journal of protistology",
        "date": "2026 Mar 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861625/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41861516",
        "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.",
        "authors": "Lee P et al.",
        "journal": "EBioMedicine",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/",
        "sentiment": {
          "label": "negative",
          "score": -0.46,
          "confidence": 0.46
        }
      },
      {
        "source": "pubmed",
        "pmid": "41859082",
        "title": "PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.",
        "authors": "Planel S et al.",
        "journal": "Frontiers in immunology",
        "date": "2026-03-28",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41859082/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41856474",
        "title": "Genomic characterization of an extensively drug-resistant high-risk Pseudomonas aeruginosa ST1971 harboring tmexCD2-toprJ2 from a Vietnamese patient with urinary tract infection.",
        "authors": "Nguyen QH et al.",
        "journal": "Journal of global antimicrobial resistance",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41856474/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41856009",
        "title": "Prevalence and diversity of gastro-intestinal nematode infections in British cattle and implications for biosecurity.",
        "authors": "Melville LA et al.",
        "journal": "Veterinary parasitology",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41856009/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "getagraph",
        "title": "Buy Signal Illumina Inc - 25 Mar 2026 @ 10:38 -> USD124.77",
        "text": "Ticker: **ILMN**\n\nExchange: **NASDAQ**\n\nTime: **25 Mar 2026 @ 10:38**\n\nPrice: **USD124.77**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/ILMN/ENG",
        "author": "jvc72",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/getagraph/comments/1s3co2k/buy_signal_illumina_inc_25_mar_2026_1038_usd12477/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "ILMN",
        "title": "Latest data on ILMN from SqueezeFinder",
        "text": "https://preview.redd.it/bv8bqdgia7rg1.png?width=906&format=png&auto=webp&s=b1fc03c8e8684ce1f3917cceb190b170fc394c6a\n\n",
        "author": "AcanthisittaHour4995",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/ILMN/comments/1s3c5vl/latest_data_on_ilmn_from_squeezefinder/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "BioTechHealthX",
        "title": "Is Illumina (ILMN) a Great Long-Term Investment?",
        "text": "",
        "author": "BioTechHealthX",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-22",
        "url": "https://reddit.com/r/BioTechHealthX/comments/1s0p0ft/is_illumina_ilmn_a_great_longterm_investment/",
        "sentiment": {
          "label": "positive",
          "score": 0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "reddit",
        "subreddit": "insiderData",
        "title": "🚨 BREAKING: We flagged Rep. Thomas H. Kean Jr.’s $ILMN buy — Illumina is now up +56% and he serves on Energy & Commerce with biotech oversight",
        "text": "We previously highlighted Rep. Thomas H. Kean Jr.’s purchase of Illumina ($ILMN) — and that stock has since delivered a strong upside.\n\nWhat makes this notable beyond the return is Rep. Kean’s committee assignments. He serves on the House Energy & Commerce Committee, which has jurisdiction over health, biotech, and technology policy — areas directly connected to companies like Illumina that develop genomic sequencing and life‑science tools.\n\nThis sector linkage helps explain why investors watch ",
        "author": "probors-com",
        "score": 6,
        "num_comments": 0,
        "date": "2026-03-11",
        "url": "https://reddit.com/r/insiderData/comments/1rqrxdg/breaking_we_flagged_rep_thomas_h_kean_jrs_ilmn/",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "reddit",
        "subreddit": "getagraph",
        "title": "Buy Signal Illumina Inc - 13 Mar 2026 @ 14:44 -> USD118.97",
        "text": "Ticker: **ILMN**\n\nExchange: **NASDAQ**\n\nTime: **13 Mar 2026 @ 14:44**\n\nPrice: **USD118.97**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/ILMN/ENG",
        "author": "jvc72",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/getagraph/comments/1rsvyz7/buy_signal_illumina_inc_13_mar_2026_1444_usd11897/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "ILMN",
        "title": "Latest data on ILMN",
        "text": "https://preview.redd.it/ogm96bvuh1mg1.png?width=897&format=png&auto=webp&s=a2c380be99135779229df621b9279ca745e8b9a0\n\n",
        "author": "AcanthisittaHour4995",
        "score": 1,
        "num_comments": 0,
        "date": "2026-02-27",
        "url": "https://reddit.com/r/ILMN/comments/1rg724z/latest_data_on_ilmn/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "getagraph",
        "title": "Buy Signal Illumina Inc - 26 Feb 2026 @ 12:46 -> USD120.61",
        "text": "Ticker: **ILMN**\n\nExchange: **NASDAQ**\n\nTime: **26 Feb 2026 @ 12:46**\n\nPrice: **USD120.61**\n\nLink: https://getagraph.com/NASDAQ/stock/live-signals/ILMN/ENG",
        "author": "jvc72",
        "score": 1,
        "num_comments": 0,
        "date": "2026-02-26",
        "url": "https://reddit.com/r/getagraph/comments/1rfh1of/buy_signal_illumina_inc_26_feb_2026_1246_usd12061/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "pennystocks",
        "title": "$QSI BIGGEST CATALYST IN ITS ENTIRE HISTORY IS THIS YEAR 2026 AND IT IS INCREDIBLY UNDERVALUED at 0.88. A full overview of its insane flagship technology \"Proteus\" and recent expectations.",
        "text": "Buckle up folks because I am here to give you the latest report & update on this undervalued stock once more. Now, let's talk about it. The bullish case for $QSI really comes down to a mix of clear upcoming catalysts and a heavily beaten-down valuation that creates ASSYMETRY IN THE PROTEOMIC MARKET (Not many know about this field which is the next biggest thing after the genome market). Personally, I see this less as a typical biotech and more like an early platform transformation which is REALL",
        "author": "nifai",
        "score": 42,
        "num_comments": 36,
        "date": "2026-03-23",
        "url": "https://reddit.com/r/pennystocks/comments/1s1jws4/qsi_biggest_catalyst_in_its_entire_history_is/",
        "sentiment": {
          "label": "negative",
          "score": -0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "reddit",
        "subreddit": "fairyloot",
        "title": "Owlcrate The Illuminae Files announced",
        "text": "Owlcrate finally announced their Illuminae Files SE! What do you guys think?",
        "author": "HistoricalSmile8234",
        "score": 103,
        "num_comments": 36,
        "date": "2026-02-27",
        "url": "https://reddit.com/r/fairyloot/comments/1rggixn/owlcrate_the_illuminae_files_announced/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "enough bio labrats, let's get some physics representation in",
        "text": "",
        "author": "Difficult-Cycle5753",
        "score": 5030,
        "num_comments": 92,
        "date": "2026-03-14",
        "url": "https://reddit.com/r/labrats/comments/1rtqvej/enough_bio_labrats_lets_get_some_physics/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "What could have cause sharp 60bp peak after Illumina library prep?",
        "text": "",
        "author": "holoqster",
        "score": 9,
        "num_comments": 43,
        "date": "2026-03-16",
        "url": "https://reddit.com/r/labrats/comments/1rv2191/what_could_have_cause_sharp_60bp_peak_after/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "makeuptips",
        "title": "How are people getting that super dewy and glowy look? My makeup always looks dead (first pic is my attempt)",
        "text": "Second pic was my inspo but it’s not turning out how I hoped 😢",
        "author": "EIIen_",
        "score": 734,
        "num_comments": 453,
        "date": "2026-03-07",
        "url": "https://reddit.com/r/makeuptips/comments/1rno7me/how_are_people_getting_that_super_dewy_and_glowy/",
        "sentiment": {
          "label": "negative",
          "score": -0.103,
          "confidence": 0.1
        }
      },
      {
        "source": "reddit",
        "subreddit": "TheBattleBricks",
        "title": "What are you doing? You really think I'm going to give up that easily? VENOMSHAK! FIREBRAND! DARKHEART! ICE DAGGER! WINDFORSE! GHOSTWALKER! ILLUMINA!",
        "text": "Well, here I go...",
        "author": "Daniyar16504",
        "score": 13,
        "num_comments": 21,
        "date": "2026-02-26",
        "url": "https://reddit.com/r/TheBattleBricks/comments/1rf9ef0/what_are_you_doing_you_really_think_im_going_to/",
        "sentiment": {
          "label": "positive",
          "score": 0.603,
          "confidence": 0.6
        }
      },
      {
        "source": "reddit",
        "subreddit": "PhightingRoblox",
        "title": "What is your opinion on Illumina",
        "text": "So I've seen how some people really like Illumina, while others dislikes them. What is your opinion on Illumina?",
        "author": "Stunning-Macaron-135",
        "score": 13,
        "num_comments": 11,
        "date": "2026-03-17",
        "url": "https://reddit.com/r/PhightingRoblox/comments/1rvxx7q/what_is_your_opinion_on_illumina/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "pennystocks",
        "title": "$QSI MEGA insider purchases filed yesterday ahead of proteus technology trials reminiscent to that of Illumina DNA sequencing technologies",
        "text": "I’ve been watching Quantum-Si Incorporated ($QSI) very closely and one thing that REALLY stood out to me recently was the insider buying. When directors start buying shares with their own money, especially when the stock is near its lows, I usually pay much more attention. Director Charles R. Kummeth stepped in and bought about 500,000 shares at roughly $0.92, putting around $460K of his own capital into the stock. Around the same time, director Paula Dowdy also bought 109,890 shares, investing ",
        "author": "Internal-Ad-5333",
        "score": 7,
        "num_comments": 11,
        "date": "2026-03-10",
        "url": "https://reddit.com/r/pennystocks/comments/1rprze9/qsi_mega_insider_purchases_filed_yesterday_ahead/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "thebrokenbindingsub",
        "title": "The Illuminae Files",
        "text": "TLDR: Looks like this set is available to ship to the US now. \n\nI've wanted this set for the past few months and every time I've clicked on the page to look at the books there was a notification that the set wasn't available to ship to the US. When I clicked on it today that notification was not there and I was able to place an order for this set. \n\nNot sure how long it's been available for US shipping but wanted to share this for those that are unaware of the shipping status change. ",
        "author": "Psyphirr",
        "score": 15,
        "num_comments": 11,
        "date": "2026-02-28",
        "url": "https://reddit.com/r/thebrokenbindingsub/comments/1rh5sr1/the_illuminae_files/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "FischRoblox",
        "title": "Selling illumina for fallen snowblade",
        "text": "20M ",
        "author": "Abject-Dependent-634",
        "score": 0,
        "num_comments": 5,
        "date": "2026-03-23",
        "url": "https://reddit.com/r/FischRoblox/comments/1s15lfs/selling_illumina_for_fallen_snowblade/",
        "sentiment": {
          "label": "negative",
          "score": -0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "reddit",
        "subreddit": "suggestmeabook",
        "title": "Books like the illuminae files",
        "text": "I NEED more books like the illuminae files!! Whether that be in unique formatting or similar sci-fi concepts (im a sucker for multiple timelines/universes) \n\nI am genuinely obsessed with the formatting of the Illuminae files, its so cool, and I love the story\n\nI yearn for more.",
        "author": "Medium-Implement228",
        "score": 1,
        "num_comments": 2,
        "date": "2026-03-23",
        "url": "https://reddit.com/r/suggestmeabook/comments/1s1r3cd/books_like_the_illuminae_files/",
        "sentiment": {
          "label": "positive",
          "score": 0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "reddit",
        "subreddit": "bioinformatics",
        "title": "Illumina NextSeq Index Issue",
        "text": "We prepared 18 shotgun metagenome libraries with an Illumina Nextera kit and combinatorial indexing with the Nextera XT index kit (24 indexes, 96 samples). Since we only had 18, we only used three of the four i5 indexes with all 6 of the i7 indexes. We had them sequenced on NextSeq.\n\nWhen we got the data back, we did get data for the expected 18 combinations of indexes although very uneven and somewhat low read numbers per sample. Upon querying the sequencing facility it turned out that 44% of t",
        "author": "cliffbeall",
        "score": 1,
        "num_comments": 3,
        "date": "2026-03-04",
        "url": "https://reddit.com/r/bioinformatics/comments/1rkov7q/illumina_nextseq_index_issue/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "NoCommute",
        "title": "New remote job at Illumina",
        "text": "Illumina is hiring a [Associate Director, Account Strategy](https://illumina.wd1.myworkdayjobs.com/en-US/illumina-careers/job/US---California---San-Diego/Associate-Director--Account-Strategy_42381-JOB-1)\n\nNoCommute is a daily newsletter with just-posted remote jobs. To get hundreds of jobs like this sent to your email 5x a week, [subscribe here](https://www.nocommutejob.com/?utm_source=reddit&utm_medium=post&utm_campaign=job_post_bot)",
        "author": "NoCommute",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/NoCommute/comments/1s2wfxm/new_remote_job_at_illumina/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "IlluminaInvestors",
        "title": "Illumina partners with Veritas Genetics to push preventive genomics",
        "text": "\nIllumina announced a strategic consortium with  aimed at advancing preventive genomics and bringing whole-genome sequencing more directly into healthcare.\n\nQuick summary of the announcement:\n\n- Illumina will provide the DNA sequencing technology, bioinformatics and AI tools.\n- Veritas will handle genome interpretation, health reports and genetic counseling.\n- The goal is to make whole-genome sequencing available at scale, potentially through healthcare systems and insurers.\n- The program also a",
        "author": "Edionyus",
        "score": 1,
        "num_comments": 1,
        "date": "2026-03-16",
        "url": "https://reddit.com/r/IlluminaInvestors/comments/1rvjgi4/illumina_partners_with_veritas_genetics_to_push/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "pwnhub",
        "title": "Coinbasecartel Targets Illumina: Data Breach Exposed",
        "text": "**A significant cybersecurity incident has led to the exposure of sensitive data from Illumina, a key player in genomics.**\n\n**Key Points:**\n\n- Illumina, a leader in genomic innovation, faced a data breach involving employee and user information.\n- A total of 12 employees and 845 users were compromised, alongside 25 third-party credentials.\n- The data leak relates to crucial genetic research and studies, raising concerns about privacy and security.\n\nOn March 15, 2026, Coinbasecartel announced a ",
        "author": "_cybersecurity_",
        "score": 2,
        "num_comments": 1,
        "date": "2026-03-15",
        "url": "https://reddit.com/r/pwnhub/comments/1ruqcoe/coinbasecartel_targets_illumina_data_breach/",
        "sentiment": {
          "label": "negative",
          "score": -0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "reddit",
        "subreddit": "FischTradingHub",
        "title": "Selling illumina for fallen snowblade",
        "text": "",
        "author": "Abject-Dependent-634",
        "score": 0,
        "num_comments": 0,
        "date": "2026-03-23",
        "url": "https://reddit.com/r/FischTradingHub/comments/1s15qjn/selling_illumina_for_fallen_snowblade/",
        "sentiment": {
          "label": "negative",
          "score": -0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "reddit",
        "subreddit": "bioinformatics",
        "title": "Help finding an analysis pipeline for Illumina scRNAseq with SNT cell hashing",
        "text": "Hi all. Please forgive the very specific question but I'm getting desperate for some help. My company is using the llumina Single Cell 3' RNA Prep kit and doing cell hashing using the Illumina Single Cell RNA T2 Synthetic Nucleotide Tag Enrichment kit. I'm trying to find a way to process the resulting FASTQs to produce the unhashed gene counts files, but Illumina support is telling me that none of their supported analysis tools will work with their own kits. I'm happy to run the unhashing analys",
        "author": "Tiny_Job_5369",
        "score": 1,
        "num_comments": 2,
        "date": "2026-03-03",
        "url": "https://reddit.com/r/bioinformatics/comments/1rk1yg9/help_finding_an_analysis_pipeline_for_illumina/",
        "sentiment": {
          "label": "positive",
          "score": 0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Illumina and Labcorp expand collaboration to broaden access to precision oncology testing",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-18",
        "url": "https://reddit.com/r/Quantisnow/comments/1rx3nm4/illumina_and_labcorp_expand_collaboration_to/",
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      }
    ]
  }
}